Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.
Selank reduced morphine withdrawal symptoms by 39.6% in rats, but its clinical relevance in humans is not established.
Where it sits
this study against the rest of the na selank amidate (n-acetyl selank amidate) corpusSummary and findings
The study investigated the effects of Selank, a peptide analog of tuftsin, on morphine withdrawal symptoms in outbred rats. A single intraperitoneal injection of Selank at a dose of 0.3 mg/kg resulted in a 39.6% reduction in the total index of morphine withdrawal syndrome. Selank also significantly attenuated convulsive reactions and increased tactile sensitivity threshold compared to the control group.
Abstract
Activity of a peptide tuftsin analogue Selank was studied in outbred rats using the naloxone-precipitated morphine withdrawal model. Single intraperitoneal injection of Selank in an anxiolytic dose of 0.3 mg/kg reduced the total index of morphine withdrawal syndrome by 39.6%, significantly (р<0.0001) attenuated convulsive reactions, ptosis, and posture disorders, and 9-fold increased the tactile sensitivity threshold in morphine-dependent rats in comparison with the group of active control; at the same time, Selank was slightly inferior to diazepam in a dose of 2 mg/kg by pharmacological activity (the decrease in total index of morphine withdrawal syndrome by 49.3% and 13-fold increase in sensitivity threshold). Thus, Selank, like diazepam, weakens the aversive signs of morphine withdrawal in rats with opiate dependence.
Background
The paper addresses the potential effects of Selank, a peptide analog of Tuftsin, on morphine withdrawal symptoms. Previous research has indicated that tuftsin and its analogs may have neuroprotective and anxiolytic properties. This study is significant as it explores the application of Selank in a context relevant to substance withdrawal, which is a critical area of research.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- rodent only, no human data
- specific numeric findings not reported
- short follow-up period not specified